Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + adefovir vs entecavir-Korea University-chronic hepatitis B
- Development stage
- Unknown
- Lead developer
- Korea University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a Phase 4 randomized clinical trial, known as the ACE (Adefovir Add-on vs Entecavir Switch) study, conducted by Korea University to evaluate treatment strategies for lamivudine-resistant chronic hepatitis B. The study compared the efficacy of adding adefovir dipivoxil to ongoing lamivudine therapy (a combination of a nucleoside and a nucleotide analogue) against switching to entecavir monotherapy (a potent nucleoside analogue). All three agents—lamivudine, adefovir dipivoxil, and entecavir—are small molecule antivirals that target the hepatitis B virus (HBV) RNA-directed DNA polymerase (reverse transcriptase), effectively inhibiting viral DNA replication and reducing viral load in patients with chronic HBV infection.
- Brand names
- Epivir-HBVZeffixHepseraBaraclude
- Other names
- ACE studyAdefovir Add-on vs Entecavir Switch in Lamivudine-Resistant Chronic Hepatitis BAdefovir Add-on vs Entecavir Switch study
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on lamivudine + adefovir vs entecavir-Korea University-chronic hepatitis B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + adefovir vs entecavir-Korea University-chronic hepatitis B.